更新于：2024-04-05

Ivermectin

伊维菌素

更新于：2024-04-05

概要

概要

基本信息

简介伊维菌素是一种小分子药物，作为谷氨酸门控氯离子通道的调节剂起作用，这一作用构成了其药理活性的基础。该药物于 1996 年 11 月获得 FDA 批准，其开发可归功于 Merck Sharp & Dohme Corp 的卓越努力。在众多治疗应用中，Ivermectin 用于治疗寄生虫感染，包括疥疮、虱子感染、丝虫象皮病和不同类型的蠕虫病。此外，它已证明在治疗红斑痤疮方面具有疗效，红斑痤疮是一种以炎症为特征的令人不安的皮肤病症。伊维菌素的广谱抗寄生虫作用使其成为旨在控制和消除高流行地区寄生虫感染的大规模药物管理计划的优秀候选者。

药物类型

小分子化药

别名

CD-5024、K-237、MK-933

+ [9]

靶点

GluCls

作用机制

谷氨酸门控氯离子通道调节剂

治疗领域

感染血液及淋巴系统疾病皮肤和肌肉骨骼疾病+ [1]

在研适应症

酒渣鼻虱病疥疮+ [9]

非在研适应症

寻常痤疮特应性皮炎扁平苔藓

原研机构

Merck Sharp & Dohme Corp.

在研机构

Merck Sharp & Dohme Corp.

浙江海正药业股份有限公司MSD KK

+ [4]

非在研机构

Galderma Holding SAGalderma Research & Development SNCTaro Pharmaceuticals U.S.A., Inc.

最高研发阶段批准上市

首次获批日期

美国 (1996-11-22),

盘尾丝虫病类圆线虫病

最高研发阶段(中国)批准上市

特殊审评孤儿药 (日本)

登录后查看首次获批时间轴

结构

分子式C47H72O14

InChIKeyVARHUCVRRNANBD-PVVXTEPVSA-N

CAS号70209-81-3

关联

316

项与伊维菌素相关的临床试验

NCT06282315 / Not yet recruiting临床4期

A Pragmatic Phase III Multicentre Clinical Trial to Evaluate the Safety and Effectiveness of a Single Dose of an Albendazole-Ivermectin Coformulation vs Albendazole for Preventive Chemotherapy of Soil-Transmitted Helminth Infections in School-Aged Children

An open-label, randomized by school, two-arm pragmatic trial, will be conducted involving two study sites in Sub-Saharan-Africa (SSA), Ghana and Kenya, to evaluate safety and effectiveness of the newly developed fixed dose combination (FDC) of albendazole (ALB) and ivermectin (IVM) as a single dose to treat Soil-Transmitted Helminths (STH), compared to the standard dose ALB single dose for the treatment and control of STH (REALISE study: Real World Evaluation of an Albendazole-Ivermectin Coformulation Safety and Effectiveness). The general objectives are to validate the benefits of FDC through this pragmatic trial in a context of mass drug administration (MDA) programme to evaluate the safety as a primary endpoint and effectiveness profile as a secondary endpoint, in a large population of school-aged children.

开始日期2024-10-01

申办/合作机构

Insud Pharma SL

[+4]

PACTR202402529220760 / Suspended临床3期

A Pragmatic Phase III Multi-Centre Clinical Trial to Evaluate the Safety and Effectiveness of a Single Dose of an Albendazole-Ivermectin Coformulation vs Albendazole for Preventive Chemotherapy of Soil-Transmitted Helminth Infections in School-Aged Children

开始日期2024-07-01

申办/合作机构

Laboratorios Liconsa SA

NCT06265870 / Not yet recruitingN/AIIT

Comparison of Outcome Between Specific Anthelminthic Treatment According to Test Results and Empirical Anthelminthic Treatment in Eosinophilic Patient

There are a few guidelines recommend about management of eosinophilia worldwide, most of guielines recommend a thorough history-taking and physical examination. Subsequently, investigations are requested based on suspected causes. In cases where parasite infection is suspected, particularly in developing countries, stool microscopy and serology are recommended. However, limitations such as low sensitivity of stool microscopy, the inconvenience of collecting multiple stool samples, and the high cost and unavailability of serology may arise. Consequently, some physicians opt for empiric anthelminthic regimens in managing eosinophilic patients, even without stool tests or if stool test results are normal. If subsequent complete blood count (CBC) results show a recovery of absolute eosinophil count, it is assumed that eosinophilia was caused by a parasite infection. While some studies demonstrate the efficacy and simplicity of this approach, there is a risk of overestimating parasite infection in eosinophilic patients, potential adverse drug reactions from unnecessary anthelminthic treatment, and the possibility of drug resistance due to inappropriate dosing. To address this gap, no study has yet compared the efficacy between specific anthelminthic treatment based on test results and empirical anthelminthic treatment in eosinophilic patients. Therefore, the investigators are conducting this study.

开始日期2024-04-10

申办/合作机构

Prince of Songkla University

100 项与伊维菌素相关的临床结果

登录后查看更多信息

100 项与伊维菌素相关的转化医学

登录后查看更多信息

100 项与伊维菌素相关的专利（医药）

登录后查看更多信息

7,179

项与伊维菌素相关的文献（医药）

2024-04-01·Veterinary Parasitology

Preparation and application of biocontrol formulation of nematode-trapping fungus-Duddingtonia flagrans

Article

作者: Wang, Xiaomin ; Ma, Yuan ; Guo, Yuan ; Gao, Mingjuan ; Liu, Tonghai ; Zhang, Yanni ; You, Xihuo ; Hao, Luyao ; Li, Qiannan ; Wang, Rui

The use of nematophagous fungi as a biological control strategy for parasitic gastrointestinal nematodes (GINs) in livestock holds promise as an innovative alternative approach. This study aimed to evaluate the clinical efficacy of a lyophilized Duddingtonia flagrans preparation, utilized in association with the anthelmintics ivermectin or albendazole, to control GINs in Tibetan sheep on a farm based in Qinghai Province. The experimental design included five groups: D. flagrans lyophilized preparation group; D. flagrans+ ivermectin combination tablets treatment group (0.6 tablets for each 10 kg b.w. containing 10⁶ chlamydospores of D. flagrans); D. flagrans+ albendazole combination capsules treatment group (5 capsules for each 10 kg b.w. containing 10⁶ chlamydospores of D. flagrans); ivermectin group (0.2 mg/kg); albendazole group (15 mg/kg), and a control group; The effect of these strategies was evaluated through the analysis of feces collected directly from the animals in each group at 24 h, 48 h, 72 h,96 h and 120 h after administration, by estimating the counts of fecal egg count reduction percentage (FECR) and larval development reduction percentage (LDR). The combination of D. flagrans lyophilized preparation with either ivermectin or albendazole yielded fecal egg and larval reduction rates of up to 100% within 72 h after oral administration, outperforming the groups treated with a single anthelmintic. Moreover, the application of the lyophilized preparation of D. flagrans chlamydospores in isolation demonstrated an 89.8% larval reduction rate. The formulation containing D. flagrans showed high predatory capacity after passage through the gastrointestinal tract of sheep and was effective for controlling gastrointestinal nematodes, which greatly reduced the pollution of the grassland, and avoid reinfection.

2024-04-01·International Journal for Parasitology: Drugs and Drug Resistance

A national survey of anthelmintic resistance in ascarid and strongylid nematodes in Australian Thoroughbred horses

Article

作者: Hughes, Kristopher J ; Hurley, John ; Stevenson, Mark A ; Carrigan, Peter ; El-Hage, Charles ; Jabbar, Abdul ; Nielsen, Martin K ; Ling, Elysia ; Bauquier, Jenni ; Cudmore, Lucy ; McConnell, Emma ; Jacobson, Caroline ; Wilkes, Edwina J A ; Ghafar, Abdul ; Gauci, Charles G ; Beveridge, Ian ; Beasley, Anne ; Abbas, Ghazanfar

This study quantified the extent of anthelmintic resistance (AR) in ascarid and strongylid nematodes against commonly used anthelmintics in Australian Thoroughbred horses. Faecal egg count reduction tests (FECRTs, n = 86) and egg reappearance period (ERP) tests were conducted on 22 farms across Australia. Faecal egg counts (FECs) were determined using the modified McMaster technique, and percent faecal egg count reduction (%FECR) was calculated using the Bayesian hierarchical model and hybrid Frequentist/Bayesian analysis method. The results were interpreted using old (published in 1992) and new (2023) research guidelines of the World Association for the Advancement of Veterinary Parasitology (WAAVP). The species composition of strongylid nematodes was detected utilising a DNA-metabarcoding method using pre- and post-treatment samples. Resistance was observed in strongylid nematodes to commonly used single-active and combination anthelmintics, including ivermectin (IVM %FECR range: 82%-92%; 95% lower credible interval (LCI) range: 80%-90%), abamectin (ABM: 73%-92%; 65%-88%), moxidectin (MOX: 89%-91%; 84%-89%), oxfendazole (OFZ: 0%-56%; 0%-31%) and its combination with pyrantel (OFZ + PYR: 0%-82%; 0%-78%). Resistance in Parascaris spp. was observed to IVM (10%-43%; 0%-36%), ABM (0%; 0%) and MOX (0%; 0%). When the new thresholds recommended by the WAAVP were used, AR was detected in six additional FECRTs for strongylids and three more tests for Parascaris spp., introducing resistance to OFZ and OFZ + PYR in the latter. Shortened ERPs (4-6 weeks) of strongylids were observed in 31 FECRTs in which AR was not detected at 2 weeks post-treatment for all the anthelmintics tested. Among cyathostomins, Cylicocyclus nassatus, Cylicostephanus longibursatus and Coronocyclus coronatus were the most prevalent species at 2 weeks post-treatment, whereas the main species appearing at five weeks following treatments with macrocyclic lactones were Cylicocyclus nassatus, Cylicostephanus longibursatus and Cylicocyclus ashworthi. After treatment with OFZ + PYR, the latter three, plus Coronocyclus coronatus and Cyathostomum catinatum, were detected at 5 weeks post-treatment. Overall, the study highlights the prevalence of AR in both ascarids and strongylid nematodes against commonly used anthelmintic products to control worms in Australian horses. The results indicate that ML combination products provided acceptable efficacy at 2 weeks. However, ERP calculations suggest that products work less effectively than previously measured. It is suggested to regularly monitor the efficacy of the anthelmintics and consider changing the worm control practices to better manage worms and AR in Australian horses.

2024-03-01·Naunyn-Schmiedeberg's archives of pharmacology

The effect of intravenous lipid emulsion (ILE) on the pharmacokinetic/toxicokinetic dispositions of ivermectin and carprofen in rabbits.

Article

作者: Akyol, Busra Aslan ; Gokbulut, Cengiz

Intravenous lipid emulsion (ILE) has been widely used as an effective antidote in both veterinary and human medicine for the treatment of acute intoxications caused by drugs and pesticides with high lipid solubility. This study was conducted to investigate the effect of ILE co-administration on the kinetic dispositions of ivermectin (IVM) and carprofen (CRP) following intravenous bolus administration at subtoxic doses in rabbits.Twenty-four male New Zealand rabbits weighing 2.78 ± 0.2 kg were used in this study. Rabbits were divided into four groups (Group 1: IVM and Group 2: IVM + ILE or Group 3: CRP and Group 4: CRP + ILE), each group consisting of 6 animals. In the IVM study, Group 1 received IVM (0.6 mg/kg) alone while Group 2 received IVM (0.6 mg/kg) and ILE (2.5 ml/kg). In the CRP study, Group 3 received CRP (12 mg/kg) alone while Group 4 received CRP (12 mg/kg) and ILE (2.5 ml/kg). In both drug groups, ILE was administered 3 times as an i.v. bolus at the 10th min and repeated 4th and 8th h after the drug administration. Blood samples were collected from the auricular vein at various times after drug administration. The drug concentrations in plasma samples were determined by high-pressure liquid chromatography. Kinetic parameters were calculated using a non-compartmental model for both CRP and IVM.The C₀ and area under the concentration-time curve from zero up to ∞ (AUC_0-∞) values were significantly greater with ILE co-administration (2136 ng/ml and 360.84 ng.d/ml) compared to the IVM alone (1340.63 ng/ml and 206 ng.d/ml), respectively. Moreover, the volume of distribution (Vd_ss) and clearance (Cl) of IVM were reduced by approximately 42% and 46% with ILE co-administration compared to IVM alone resulting in a reduction of the distribution and slower elimination, respectively. Similar differences in C₀, and Vd_ss values were also observed in CRP with ILE co-administration compared to CRP alone. ILE co-administration changed significantly the kinetic profile of both IVM and CRP in rabbits, supporting the lipid sink theory in which highly lipid-soluble compounds are absorbed into the lipid phase of plasma from peripheral organs such as the heart and brain affected by the acute toxicity of the compounds.

项与伊维菌素相关的新闻（医药）

2024-03-22

·EndPoints

FDA to delete 'You are not a horse' post and others in ivermectin case settlement

The FDA has agreed to delete years-old social media posts discouraging the use of ivermectin to treat Covid-19 as part of a settlement agreement in Texas federal court. The case was brought by three doctors in 2022 over an FDA campaign designed to combat misinformation around ivermectin and dissuade people from taking it for Covid-19. The campaign struck an unusual tone for the agency, which included posts such as “You are not a horse,” and “Seriously, y’all. Stop it.” You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

专利侵权

2024-03-01

·生物制品圈

百年默沙东：药物是为人类而生产，不是为追求利润而制造

当我们回溯默沙东的发展史，有一条清晰的曲线与企业发展紧密相连——不断增长的研发投入。2022年，默沙东研发投入达135亿美元，在行业中位居前列。高研发投入带给默沙东的，不仅是在激烈市场竞争中破浪前行的坚实桨板，更意味着研发创新的不断精进，以及更多更好的药品疫苗，而这些创新成果将实质性地拯救数以万计人的生命，并改善其家庭生活。历史为我们展卷的，并非一盘过时的“棋局”。每每回顾来路，新的一局早已开始，生生不息……如果对比下各大药企2022年的研发投入，便会发现无论是绝对值还是百分比，默沙东（Merck & Co., Inc.）都在行业中位居前列¹²³。135亿美元的高投入¹，带给默沙东的，不仅是在激烈市场竞争中破浪前行的坚实桨板，更意味着研发创新的不断精进，以及更多更好的药品疫苗，而这些创新成果将实质性地拯救数以万计人的生命，并改善其家庭生活。而在仅一年之后的2023年，默沙东全年研发支出已升至305亿美元，占比超默沙东2023全年销售额的一半以上⁴。默沙东，这家全球知名制药巨头，以其独特的经营哲学和研发理念在医药行业中独树一帜。它并非以盈利为首要目标，而是以不懈努力和坚定信念，不走捷径、脚踏实地，赢得了受人尊敬、基业长青的崇高声誉，也“顺便”在财务上取得了辉煌的成绩。默沙东中国当我们回溯其发展史，会发现默沙东的成功并非偶然，一条清晰的曲线与企业发展紧密相连——不断增长的研发投入。早在上世纪20年代，默沙东便率先聚集了一批科学家团队，为日后的默沙东实验室打下坚实基础，为未来的疫苗药物研发注入源源动力，这使得默沙东成为了今天诸多行业前沿原研疫苗药物的摇篮。前任默沙东首席执行官、总裁兼董事会主席P·罗伊·瓦杰洛斯（P. Roy Vagelos）常强调，默沙东“与众不同”。集团基业长青的核心竞争力，也同样源于有所取舍的深研专精，勇气加持的国际眼光，以及一系列恰到好处的收购、剥离以及国际和本土合作，而其贯穿始终的精神支柱，是“对创新的执著，对生命的敬重”。P·罗伊·瓦杰洛斯医学博士合并之路：三次巨头联手没有历史上三次举足轻重的合并，便没有默沙东逾百年的“增辉生命”。时间回溯至一战后，默沙东和母公司分家，与精细化学品制造商PWR（Powers-Weightman-Rosengarten）合并，不仅获得了宝贵的资金和运营资本，而且为扎根研发奠定了坚实基础。 26年后——1953年，研发投资已带给默沙东丰厚的回报，维生素、抗生素计划也获得了巨大成功。但此时医药行业正经历翻天覆地的变革，成品药市场潜力巨大。默沙东毅然决定走出化学品生产，投身成品药生产销售疆界。但为实现这一转型，默沙东需要一家经验丰富的医药公司为其引路。事后看来，没有比盈利性药企沙东（Sharp & Dohme）公司更合适的选择。沙东公司的产品和管线与默沙东互补，合并后的新公司沿用“默沙东”的名称和声誉，并吸收了沙东公司在美国三地的制造设施，获得了足够的空间来发展壮大。默沙东与沙东公司合并但历史的车轮并未给默沙东驻足停歇太久的机会。上世纪中后期，默沙东再次面临挑战——几款重磅药失去专利，研发管线的流动速度也大大放缓。公司需要重新审视企业战略，寻求多元化的发展道路。2009 年，默沙东收购先灵葆雅（Schering-Plough）。先灵葆雅的收入绝大部分来自美国以外的国家和地区，全球业务网络也更为广泛；产品线与默沙东相似，但在研发实力和市场布局上有所不同，正是这些共性与差异激发了双方的协同效应。与先灵葆雅合并后的默沙东，延展了生物、健康护理及动物健康产品线，业务更加多元化。全球化：迈出更大步履，造福更多生命一家公司的业务网络如果只覆盖北美、欧洲和日本，就没资格称自己是国际企业。事实上，默沙东一直在寻求机会将其业务网络扩展到西方市场以外。早在上世纪 80 年代末，默沙东就开始将目光投向了拉丁美洲、中国、非洲等新兴市场，但真正从战略上着眼于新市场的开发，是从福维泽（Kenneth C. Frazier）担任全球人类健康负责人时开始。前默沙东首席执行官福维泽彼时，默沙东的管线正遭遇挑战，摆在面前的经营战略只有两种：向现有客户销售新产品，或向新客户销售现有产品。 “在西欧、北美以及日本之外的国家和地区，仍有很多患者亟需我们的解决方案。我们需要找到方法，让默沙东的药物和疫苗惠及更多人群，实现提高医疗服务可及性的承诺。”福维泽说道。继与沙东公司合并、扩大了全球业务后，在20世纪50年代和60年代期间，多家子公司和合作伙伴加入默沙东，默沙东国际（MSD International）自此成立。随着与先灵葆雅的合并以及公司业务足迹的扩张，默沙东在拓展新兴市场业务方面已变得更有底气，因而迅速将巴西、俄罗斯、印度和中国等市场列为优先发展对象。全球化为默沙东带来了巨大的增长机会，但要抓住机会，还需做很多功课：不仅需明确自身优势和产品属性，跟新兴市场建立连接，逐步构筑对本地监管环境、定价模式、商业架构等多方面认知；而且要聆听并考量这些新兴国家公私组织机构和医患对于企业自身的看法，以对外实现和监管部门的有效沟通、对内在日常工作中贯彻组织价值观和企业文化，让由内到外的利益相关方均感受到默沙东的巨大价值，从而愿意携手并进。在亚太市场也是如此。为了更好地理解和融入，默沙东迎来了新成员大卫·安斯蒂斯（David Anstice），土生土长的澳大利亚人。其贡献不仅体现在业务增长上，更重要的是他为团队带来了新的思维方式和工作方法。他坚信，只有真正融入当地市场，理解本土文化和消费者需求，才能真正实现业务的可持续发展。大卫·安斯蒂斯 (David Anstice)这一理念深深影响了默沙东在亚太区的战略决策和业务发展，并帮助其在新环境中摸索出了一条长远的发展之路。在安斯蒂斯的领导下，默沙东在亚太的业务发展如火如荼，也为今天默沙东中国的稳健前行铺平了道路。自1992年进入中国，30余年来，默沙东已成为中国医疗生态圈中值得信赖的合作伙伴。其在北京设有研发中心，在杭州、宁波和天津设有工厂，实现了研发、制造和商业运营的三擎合一；带来疫苗、肿瘤、糖尿病和抗感染等领域约30种药品和疫苗，从疾病预防到治疗，满足未尽需求，造福患者大众。今天，中国已是默沙东全球增长战略中至关重要的一部分，更是其在美国之外的第二大市场⁵。2023年财报显示，默沙东在中国区的营收已达67.1亿⁴。从收购到剥离，全神贯注精我所长Cubist医药公司在推出治疗革兰氏阳性细菌感染的抗生素时，引起了默沙东的注意。为进一步扩大自身抗感染战线，2014年，默沙东宣布收购Cubist医药公司。差异化和协同性为默沙东“牵手”Cubist的原因。尽管Cubist规模较小，但其抗生素研发实力处于行业前列。默沙东深耕抗感染领域多年，这次收购也为其搭建了更广阔的应对抗生素耐药性的实战舞台。但默沙东并未满足于现状，而是积极寻求新的发展机会，并很快注意到动物保健市场的巨大需求和潜力。对于默沙东而言，动物保健与人类健康业务非常相似，都基于科学的研究和开发，且与默沙东“增辉生命”的百年追求息息相关。今日的默沙东动物保健业务已价值数十亿美元，除关注家畜健康外，还非常重视宠物的福祉。 2019年，默沙东动物保健收购Antelliq集团，将监测和跟踪动物健康状态的数字业务纳入麾下。目前，默沙东动保已成长为一家秉持“整体健康”理念的公司，不仅关注家畜和宠物的药品和疫苗，还提供科学喂养、宠物识别芯片、DNA测试、诊断及监测等一系列整体性的动物健康解决方案。默沙东创新性地提出并持续践行“同一健康”理念，即人类健康和动物健康互为依存，共同助力人类、动物和环境和谐共生的大健康共同体。 “同一健康”即人类健康和动物健康互为依存除了收购，默沙东还通过剥离独立优势业务，提高企业的运营效率和盈利能力。当前，剥离独立优势业务在医疗行业愈发普遍，这一举措可使母公司更聚焦核心领域、优化资源使用，从而实现业绩长期增长；同时也可发挥独立公司优势，以更聚焦的运营、更强大的灵活度，应对多变市场。2007年，先灵葆雅收购了欧加农生物科学（Organon BioSciences）——一家专注开发家用尿妊娠测试用品的荷兰医药公司⁶。两年后，默沙东与先灵葆雅合并。彼时的高管团队意识到，默沙东的优势似乎难以从新的组织结构中脱颖而出；在深入探讨后，公司决定将欧加农剥离，而默沙东则更专注于肿瘤、抗感染和慢性病等核心业务。 2021年6月，独立上市公司欧加农（Organon & Co.）正式成立，后更名为“欧加隆”，专注于女性健康。“伴随抗肿瘤免疫疗法的地位日益重要，我们决定特别聚焦疫苗、院内专科医疗、肿瘤及动物保健等四大业务支柱。面对百余种产品，‘一网打尽’显然是行不通的。为能更保质保量地满足广大民众对创新药品和疫苗的需求，我们必须拿出更好的组织战略发展方案。”福维泽总结道。这两个指标做到极致，就能改变世界将药物和疫苗高效高质送抵患者，是默沙东始终坚守的使命。除了业务专精，公司还积极开展慈善活动和捐赠计划，以提升健康可负担性和可及性，并将这一“铁肩担道义”的精神和社会责任理念融入研发、制造和商业活动的每个环节。早在上世纪50年代，创始人乔治·W·默克就强调：我们应当永远铭记，药物是为人类而生产，不是为追求利润而制造的。只要我们坚守这一信念，利润必将随之而来。身为1986-1994年默沙东首席执行官、总裁兼董事会主席的瓦杰洛斯，正是这一核心价值观的继承者。在其领导下，默沙东迈入了分子时代：不仅完成了十几种药物的上市工作，还前瞻性地启动了默沙东“药物平等获取计划”和“免疫计划”，旨在让全球更多患者与公众获得高质量的药物和疫苗。最重要的是，瓦杰洛斯让默沙东名利双收。无论是向中国低价转让重组乙肝疫苗技术，还是向非洲无偿捐赠治疗河盲症的伊维菌素，都让默沙东广受赞誉。其继任者福维泽深受这一理念的影响，并于2011年带默沙东进入了其成长中的又一个“关键十年”。福维泽接任默沙东董事会主席兼首席执行官后，令人意想不到地提出——废除默沙东先前长期发布的每股收益指标，且要求董事会通过800亿美元的研发投资案。为默沙东能长久“ 科学挂帅”，福维泽做出了当时最对的决定，在稳住公司短期股价与保住长期成功间取得了平衡。健康可及性的重要指标，一是帮助了多少人，二是给予了多大帮助。如果将这两个指标做到极致，就能改变世界。除了通过整顿领导班子振兴默沙东实验室，福维泽也于2011年提出了大胆倡议：投资5亿美元启动“默沙东关爱母亲”行动（MSD for Mothers），帮助孕产妇获得更安全健康的妊娠和生产，迄今已惠及全球1,810多万妇女。“默沙东关爱母亲”行动福维泽做出了无数类似的“ 艰难决定”。而最引人瞩目的，无疑是2017年退出美国前总统特朗普组建的美国制造业委员会。只因默沙东始终坚信，企业的力量之源和国家一致，均是对多元种族、文化和理念的包容接纳。 2021年，戴福财（Robert M. Davis）接替福维泽成为新任首席执行官并担任董事会成员。虽与前任背景迥异，但同样拥有经营商业的天赋和对生命的尊重与关怀。在戴福财的领导下，默沙东并未拘泥于“内生”，而是放眼全球全行业展开“狩猎”，跳上了内生研发、外延收购、联合用药的“三驾马车”。继2014年将健康消费品业务出售给拜耳、2017年收购免疫领域德国初创企业Rigontec以辅助PD-1研发，默沙东于2023年秋冬与第一三共就三种抗体药物偶联物ADC，签订了全球开发和商业化协议；并收购 Caraway，共同探索生物科技领域、加码神经退行性疾病和罕见病产品管线；还通过子公司收购Harpoon Therapeutics，获得一系列T细胞接合器在研疗法。戴福财说：“人类对于生物学的认知、追求科学的方式都在发生巨变，默沙东必须适应，为立足未来而不断合作、学习、发展和创新，这样才能永续造福患者。” 截至2022年底，四价及九价HPV疫苗为默沙东贡献了近69亿美元的营收¹，直至2023年11月已惠及4,300万中国适龄女性。其肿瘤免疫治疗药物也已在2023年12月前取得13项在华批准，包含12个适应证和1个新增剂量方案，覆盖8个癌种和首个基于特定生物标志物状态的适应证，助力拥抱癌症有所医、可能治愈的新时代。目前，默沙东拥有抗细菌、抗真菌、抗病毒三条线，在持续的投入研发下，公司在急性和重症感染、CMV巨细胞病毒、HIV人类免疫缺陷病毒等多个治疗领域均有所贡献。2023年第三季度业绩来看，默沙东全球总销售额达159.62亿美元；上年同期为149.59亿美元，同比增长7%⁷⁸；季度净利润47.45亿美元，同比增长46%⁹。近日发布的2023年财报显示，默沙东仅一年便服务5亿多人，销售额达601亿美元，更投资其中超50%的300多亿美元用于研发¹⁰，持续推进下一代创新发现。毫无疑问，这家公司在赚得可观利润的同时，也让千万人“赚”得了人生最珍贵的财富——健康。回看默沙东的百年发展，我们不禁会思考这样一个问题：是什么驱动着这家制药巨头不断创新和发展？答案或许是——不断拯救生命，改善健康的情怀与担当。“药物是为人类而生产，不是为追求利润而制造”，相信这一理念将继续带领这家国际制药巨头前行不辍。崭新的棋局已然落子，前方山峦沟壑、挑战犹存，但“增辉生命”的希望恒然光照。 1 Merck Announces Fourth-Quarter and Full -Year 2022 Financial Results2 罗氏22年财报3 强生_4Q22-Press-Release-with-attachments4 2024 Financial Highlights Package 4Q23_15 MSD.Financial-Highlights-Package-3Q236 National Library of Medicine. A historical argument for regulatory failure in the case of Primodos and other hormone pregnancy tests7 MSD. Our Q3 2023 earnings report8 MSD. MSD’s Q3 2022 earnings report9 Macrotrends. Merck Net Income 2010-2023 | MRKmei10 Merck Announces Fourth-Quarter and Full-Year 2023 Financial Results （文中图片均来自默沙东）识别微信二维码，添加生物制品圈小编，符合条件者即可加入生物制品微信群！请注明：姓名+研究方向！版权声明本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观点，不代表本站立场。

疫苗并购

2023-12-07

·PRNewswire

ProgenaBiome Given Presidential Award at ACG Conference for Microbiome Research

VENTURA, Calif., Dec. 7, 2023 /PRNewswire/ -- Last month, ProgenaBiome™, a genetic research lab dedicated to studying and understanding the the microbiome, received yet another presidential award from the American College of Gastroenterology (ACG) at the ACG Annual Scientific Meeting in Vancouver. This marks their fourth year of attendance at the conference and third consecutive year of presidential-level recognition for research on the microbiome. Continue Reading Photo courtesy of Dr. Sabine Hazan from the ACG Conference in Vancouver, Canada. Dr. Sabine Hazan with ProgenaBiome's submitted abstracts at the 2023 ACG Conference in Vancouver, Canada. The ACG conference brings GI physicians and researchers from around the world to discuss the latest clinical information in gastroenterology and hepatology. According to ACG, each year less than 5% of accepted abstracts are awarded the presidential distinction for "high quality, novel, unique, and interesting research." ProgenaBiome was given the award for their research on commercial Probiotic products. Their groundbreaking findings indicated significant discrepancies between probiotic food label claims and their contents. More specifically, only five out of 25 tested commercially available products with label-promised Bifidobacteria – an organism essential for a healthy microbiome – truly contained the bacteria. Dr. Sabine Hazan, world-renowned gastroenterologist, and founder of ProgenaBiome, explained that this research raises an important, though disheartening, fact about the commercial health industry. "The abstract on probiotics shows the need for quality testing of health products by an independent party. But more importantly, it shows that there is marketing and influencing that exists to mislead consumers," said Hazan. In addition to this research, ProgenaBiome submitted 3 abstracts which present cutting edge research that could majorly alter understanding and treatment of the microbiome. The second abstract introduced the findings that support the concept of an individualized microbiome, meaning gut bacteria varies by individual. This research suggests a complex interplay of host-specific factors that play a role in microbiome diversity. The third abstract defied the narrative on Ivermectin, showing that Ivermectin has a role on the microbiome short-term. Which could benefit investigators using it for various therapeutic interventions. Hazan believes that in this growing industry, ProgenaBiome's authentic microbiome research is the "key to science," even if met with controversy. Hazan noticed a growing number of articles have been retracted in the last four years. "This goes against the essence of science. Science is about controversy and defying the narrative. Science is about 'prove me wrong.' Retraction of research should never occur for this reason," said Hazan. The fourth abstract ProgenaBiome submitted describes "significant microbiome changes" in patients suffering from Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD) following treatment with Bovine IgG. These findings suggest that Bovine IgG may influence essential gut bacteria – specifically Alisteps, Bacteroides, Bifidobacteria, Actinobacteria, Bacteroidetes and Proteobacteria – to help manage IBS and IBD symptoms. These abstracts are the result of ProgenaBiome's community of specialized physicians who explore topics that others in the medical community see as too daunting or controversial to study. "We do the research nobody wants to do because of expense and controversial nature, but it is research everyone wants to know. Anything short of challenging the narrative is not science – it's propaganda," said Hazan. ProgenaBiome is a standalone research company that is not backed by a large pharmaceutical corporation, but it is interested in guiding the pharmaceutical industry towards this new frontier of research. Their research is funded by individual donations and proceeds from sales products "Lets Talk Sh!T" book and Biomeboosters. "We cannot do this without support from our community, so please consider donating before the end of the year to the Microbiome Research Foundation ," said Hazan. Read more about ProgenaBiome's research, mission, and register to the newsletter through their webpage, progenabiome.com. For more timely information, follow Dr. Hazan on X @SabinehazanMD and Instagram @dr.sabinehazan. For more, visit: Media Contact: 800-380-7764 [email protected] Author: Jamie Miller [email protected] 404-422-9433 SOURCE ProgenaBiome

微生物疗法

100 项与伊维菌素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00804	伊维菌素	D11AX22 P02CF01	DB00602

研发状态

适应症	最高研发状态	国家/地区	公司
酒渣鼻	批准上市	美国更多	Galderma Laboratories LP 更多
盘尾丝虫病	批准上市	美国更多	Merck Sharp & Dohme Corp. 更多
类圆线虫病	批准上市	中国更多	浙江海正药业股份有限公司更多
新型冠状病毒感染	临床2期	保加利亚更多	MedinCell SA 更多
寻常痤疮	无进展	加拿大更多	Galderma Research & Development SNC 更多

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04848688 (CTgov)	临床3期	类圆线虫病	332	Placebo+Moxidectin 2 mg (Moxidectin)	遞顧艱衊淵膚鏇艱壓醖(鹽鑰膚網繭願窪築廠憲) = 襯積積鏇構鹽鏇夢構醖糧觸獵艱選夢簾齋蓋鑰 (壓築積鹽鹽衊鏇壓範積, 獵夢壓膚鑰範範齋夢觸 ~ 淵醖觸衊憲壓積膚觸積) 更多	-	2024-01-24
				Placebo+Ivermectin 3 mg (Ivermectin)	遞顧艱衊淵膚鏇艱壓醖(鹽鑰膚網繭願窪築廠憲) = 獵醖觸糧衊憲襯糧廠繭糧觸獵艱選夢簾齋蓋鑰 (壓築積鹽鹽衊鏇壓範積, 築鏇製積壓壓糧築繭願 ~ 簾膚膚鬱鑰願衊獵夢網) 更多
NCT03967054 (CTgov)	临床3期	疟疾	4,124	Ivermectin (Ivermectin Mass Drug Administration)	壓選網齋獵繭餘艱遞鹽(壓獵簾艱構獵淵壓選製) = 襯鏇夢積顧鑰鏇壓糧願鹹鑰膚襯獵膚壓鑰鹹遞 (廠艱蓋繭窪壓齋糧襯蓋, 顧鏇醖鹹廠壓遞鏇餘遞 ~ 顧鹹餘齋夢鬱遞餘觸遞) 更多	-	2024-01-11
				Placebo oral tablet (Placebo Mass Administration)	壓選網齋獵繭餘艱遞鹽(壓獵簾艱構獵淵壓選製) = 構觸淵鹹廠願觸鏇窪壓鹹鑰膚襯獵膚壓鑰鹹遞 (廠艱蓋繭窪壓齋糧襯蓋, 鏇衊艱襯積淵蓋選壓襯 ~ 壓網淵襯遞壓獵繭廠餘) 更多
NCT05894538 (CTgov)	临床3期	新型冠状病毒感染	1,459	Ivermectin (Arm D - Ivermectin 600)	壓醖鑰鹽鏇廠憲觸齋淵(網糧憲餘顧製壓艱網壓) = 夢選製淵憲壓範顧獵網夢網夢構鏇網觸鑰艱醖 (廠衊齋遞淵鏇遞壓糧壓, 艱鏇壓憲膚遞窪衊膚廠 ~ 鹽齋艱壓鑰積夢網選衊) 更多	-	2023-09-28
				Placebo (Arm D - Placebo)	壓醖鑰鹽鏇廠憲觸齋淵(網糧憲餘顧製壓艱網壓) = 遞廠醖積餘簾築網築簾夢網夢構鏇網觸鑰艱醖 (廠衊齋遞淵鏇遞壓糧壓, 遞繭積獵鏇製築鹽鑰獵 ~ 齋範願選淵齋餘築餘鑰) 更多
NCT04510194 (CTgov)	临床3期	新型冠状病毒感染	1,323	Metformin (Treatment Arm - Metformin Only Group)	簾窪網衊鬱網蓋築鏇鑰(淵繭憲鬱顧齋繭夢鑰窪) = 獵鬱鹽構鏇襯鹽願壓憲鹹醖觸鹹襯壓願餘壓鹽 (淵淵艱鹽範鏇艱遞選壓, 範網鏇齋鏇窪衊壓蓋壓 ~ 糧獵觸蓋繭繭觸齋蓋範) 更多	-	2023-07-13
				Placebo (Treatment Arm - Placebo Group)	簾窪網衊鬱網蓋築鏇鑰(淵繭憲鬱顧齋繭夢鑰窪) = 網窪衊糧齋蓋膚餘顧製鹹醖觸鹹襯壓願餘壓鹽 (淵淵艱鹽範鏇艱遞選壓, 選淵廠淵鬱鏇襯憲醖願 ~ 壓醖顧鹹獵繭顧鏇鏇夢) 更多
WCD2023	N/A	疥疮	-	ivermectin (Community residents)	齋鬱鹽醖廠醖壓簾範齋(襯餘範齋積選繭鑰鹹醖) = 遞顧鏇餘獵膚鏇選築蓋繭獵膚憲遞遞壓夢醖積 (齋廠觸醖廠簾艱製築構 )	-	2023-07-06
WCD2023	N/A	酒渣鼻	-	Ivermectin 1% cream and doxycycline 40 mg	觸淵遞觸艱構鹽衊構糧(憲糧鹹繭憲艱淵夢顧餘) = 獵觸糧構窪獵顧壓鏇醖廠窪糧鬱網衊窪淵襯製 (製遞鬱窪廠糧膚淵積襯 )	-	2023-07-03
				Ivermectin 1% cream and Placebo	觸淵遞觸艱構鹽衊構糧(憲糧鹹繭憲艱淵夢顧餘) = 憲鏇鏇積壓積願鑰膚繭廠窪糧鬱網衊窪淵襯製 (製遞鬱窪廠糧膚淵積襯 )
NCT04188301 (CTgov)	临床2期	盘尾丝虫病	154	Albendazole+Ivermectin (IVM + ALB)	襯製醖獵憲積襯繭範繭(願膚遞顧構製艱製餘鬱) = 觸獵繭築蓋鬱襯壓壓醖簾窪網簾獵獵鹽製壓膚 (願窪廠憲積糧膚構憲簾, 繭積築廠製壓襯壓鹽網 ~ 襯選選鏇憲鬱選積鏇鏇) 更多	-	2023-05-10
				albendazole+ivermectin+diethylcarbamazine (IDA x 1 Dose)	襯製醖獵憲積襯繭範繭(願膚遞顧構製艱製餘鬱) = 鑰齋鹹鹽憲範蓋夢醖積簾窪網簾獵獵鹽製壓膚 (願窪廠憲積糧膚構憲簾, 齋膚膚餘網範積膚築蓋 ~ 窪壓鬱齋糧選窪餘襯壓) 更多
NCT03250624 (CTgov)	临床2期	特应性皮炎	63	CD5024 0.3% cream (CD5024 0.3% Cream)	選醖選鹹鏇夢構選積壓(鏇積窪壓齋廠簾觸鹹鹽) = 淵構遞憲憲積顧鬱鏇鹽鹽憲鑰選膚積積艱鹹鏇 (鏇窪網壓鏇鏇醖廠膚衊, 築蓋願積醖顧壓積艱餘 ~ 願壓膚鏇簾蓋選範壓製) 更多	-	2023-05-01
				Placebo (Placebo)	選醖選鹹鏇夢構選積壓(鏇積窪壓齋廠簾觸鹹鹽) = 窪積構鬱窪選窪觸夢窪鹽憲鑰選膚積積艱鹹鏇 (鏇窪網壓鏇鏇醖廠膚衊, 壓網襯齋艱夢構壓網顧 ~ 鹹網鬱鏇範獵製憲觸鏇) 更多
NCT05736861 (CTgov)	临床3期	新型冠状病毒感染	1,800	Ivermectin (Arm A - Ivermectin 400)	糧鹹鹹憲齋繭簾憲鬱齋(網齋範觸網衊範糧醖蓋) = 繭餘壓網夢觸糧鏇憲齋窪選蓋夢遞壓獵鹽廠廠 (範糧鹽艱齋鏇築鹹餘簾, 繭膚鏇齋築鹹窪簾廠製 ~ 壓鹹鹹憲積憲鏇膚簾願) 更多	-	2023-04-11
				Placebo (Arm A - Placebo)	糧鹹鹹憲齋繭簾憲鬱齋(網齋範觸網衊範糧醖蓋) = 壓艱鹹鹽網醖遞餘鏇醖窪選蓋夢遞壓獵鹽廠廠 (範糧鹽艱齋鏇築鹹餘簾, 簾蓋蓋鏇鹽膚顧範獵獵 ~ 齋繭願廠襯壓蓋遞齋獵) 更多
NCT05041907 (PLATCOV, Pubmed)	临床2期	新型冠状病毒感染	205	Monoclonal antibodies casirivimab and imdevimab (600mg/600mg)	繭齋築廠網衊鹽窪襯遞(鹽願憲鏇鑰築夢構齋淵) = 廠鏇鏇夢繭鑰膚網簾餘醖醖範膚顧鏇餘廠糧鬱 (製鑰網襯範醖醖範蓋鏇, +7.0% ~ +115.1%)	-	2023-02-21